What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?

What happened: Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or refractory multiple myeloma, with the results positioned as supportive evidence for potential accelerated approval. Key numbers: Reported market value of about $122.0b. Fair value cited at $66.71. Why it matters: The data strengthen the view that next generation oncology assets can take a larger share of future revenue as older therapies face patent pressure, though analysts still factor in declining revenue and earnings over the next few years. Market: -2.6% by next close ($57.58 on Oct 12), +12.0% YTD

Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or refractory multiple myeloma, with the results positioned as supportive evidence for potential accelerated approval.

The data strengthen the view that next generation oncology assets can take a larger share of future revenue as older therapies face patent pressure, though analysts still factor in declining revenue and earnings over the next few years. Market: -2.6% by next close ($57.58 on Oct 12), +12.0% YTD